We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AMAG Q3 Loss Wider Than Expected, Revenues Lag Estimates
Read MoreHide Full Article
AMAG Pharmaceuticals, Inc. incurred a loss of 70 cents per share in the third quarter of 2019, wider than the Zacks Consensus Estimate of a loss of 51 cents but narrower than the year-ago quarterly loss of 77 cents.
Moreover, quarterly revenues of $84.1 million were down approximately 31.2% from $122.2 million a year ago. The top line also missed the Zacks Consensus Estimate of $89 million.
Shares of AMAG have plunged 34.5% year to date against the industry’s increase of 1.3%.
Quarter in Detail
Makena subcutaneous auto-injector recorded sales of $41.3 million, reflecting an increase of 5.4% year over year. The revenue figure was consistent on a sequential basis.
Notably, in second-quarter 2019, AMAG made a mutual decision with Prasco to exit the generic intramuscular (IM) market due to the ongoing supply issues and increased generic competition. As a result, Makena IM generated negative revenues in the third quarter compared with the second quarter, which witnessed a significant loss of market share for the IM brand.
Feraheme sales were $44.2 million in the third quarter, accounting for a 19.8% rise year over year. Intrarosa generated sales of $5.6 million in the reported quarter compared with $4.9 million in the year-ago period.
Operating expenses including the cost of product sales were $102.2 million, down 27.8% from the year-earlier quarter. During the third quarter, the company did not recognize any Makena IM amortization.
2019 Outlook
AMAG lowered the mid-point of its revenue guidance for 2019. The company now expects full-year revenues of $320-$330 million compared with the previous estimate of $325-$355 million, mainly due to trimmed expectations for Intrarosa and the negative IM revenues.
Other Updates
We remind investors that in October 2019, AMAG announced that the FDA’s Bone, Reproductive and Urologic Drugs Advisory Committee has analyzed data from the PROLONG trial on Makena. The drug is approved to reduce preterm birth in pregnant women, who have had a prior spontaneous preterm delivery. Nine of 16 advisory committee members voted to recommend the FDA to pursue the withdrawal of Makena from the market while the rest voted in favor of keeping the product in the market under an accelerated approval and requesting a new confirmatory trial. The regulatory agency will consider the advisory committee's recommendation when making its decision but is not bound by the same.
In a separate press release, the company announced that as of now, Makena’s approval and product label are intact.
Meanwhile, in September 2019, AMAG launched Vyleesi (bremelanotide injection), a melanocortin receptor agonist indicated for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Vyleesi is the first treatment for this patient population that can be self-administered in anticipation of sexual activity. The drug was approved in June 2019.
Per the company, more than 1,300 healthcare providers prescribed Vyleesi adding to above 3,000 prescriptions received by specialty pharmacy partners to date.
AMAG Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Anika’s earnings estimates have been revised 16% upward for 2019 and 19.1% for 2020 over the past 60 days. The stock has skyrocketed 103.9% year to date.
Acorda’s loss per share estimates have been narrowed 20.4% for 2019 and 43% for 2020 over the past 60 days.
BeiGene’s loss per share estimates have been narrowed 2.2% for 2019 and 0.3% for 2020 over the past 60 days.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
Image: Bigstock
AMAG Q3 Loss Wider Than Expected, Revenues Lag Estimates
AMAG Pharmaceuticals, Inc. incurred a loss of 70 cents per share in the third quarter of 2019, wider than the Zacks Consensus Estimate of a loss of 51 cents but narrower than the year-ago quarterly loss of 77 cents.
Moreover, quarterly revenues of $84.1 million were down approximately 31.2% from $122.2 million a year ago. The top line also missed the Zacks Consensus Estimate of $89 million.
Shares of AMAG have plunged 34.5% year to date against the industry’s increase of 1.3%.
Quarter in Detail
Makena subcutaneous auto-injector recorded sales of $41.3 million, reflecting an increase of 5.4% year over year. The revenue figure was consistent on a sequential basis.
Notably, in second-quarter 2019, AMAG made a mutual decision with Prasco to exit the generic intramuscular (IM) market due to the ongoing supply issues and increased generic competition. As a result, Makena IM generated negative revenues in the third quarter compared with the second quarter, which witnessed a significant loss of market share for the IM brand.
Feraheme sales were $44.2 million in the third quarter, accounting for a 19.8% rise year over year. Intrarosa generated sales of $5.6 million in the reported quarter compared with $4.9 million in the year-ago period.
Operating expenses including the cost of product sales were $102.2 million, down 27.8% from the year-earlier quarter. During the third quarter, the company did not recognize any Makena IM amortization.
2019 Outlook
AMAG lowered the mid-point of its revenue guidance for 2019. The company now expects full-year revenues of $320-$330 million compared with the previous estimate of $325-$355 million, mainly due to trimmed expectations for Intrarosa and the negative IM revenues.
Other Updates
We remind investors that in October 2019, AMAG announced that the FDA’s Bone, Reproductive and Urologic Drugs Advisory Committee has analyzed data from the PROLONG trial on Makena. The drug is approved to reduce preterm birth in pregnant women, who have had a prior spontaneous preterm delivery. Nine of 16 advisory committee members voted to recommend the FDA to pursue the withdrawal of Makena from the market while the rest voted in favor of keeping the product in the market under an accelerated approval and requesting a new confirmatory trial. The regulatory agency will consider the advisory committee's recommendation when making its decision but is not bound by the same.
In a separate press release, the company announced that as of now, Makena’s approval and product label are intact.
Meanwhile, in September 2019, AMAG launched Vyleesi (bremelanotide injection), a melanocortin receptor agonist indicated for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Vyleesi is the first treatment for this patient population that can be self-administered in anticipation of sexual activity. The drug was approved in June 2019.
Per the company, more than 1,300 healthcare providers prescribed Vyleesi adding to above 3,000 prescriptions received by specialty pharmacy partners to date.
AMAG Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
AMAG Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | AMAG Pharmaceuticals, Inc. Quote
Zacks Rank & Other Stocks to Consider
AMAG currently carries a Zacks Rank #2 (Buy). Other top-ranked stocks from the healthcare sector include Anika Therapeutics Inc. (ANIK - Free Report) , Acorda Therapeutics, Inc. and BeiGene, Ltd. (BGNE - Free Report) , all sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Anika’s earnings estimates have been revised 16% upward for 2019 and 19.1% for 2020 over the past 60 days. The stock has skyrocketed 103.9% year to date.
Acorda’s loss per share estimates have been narrowed 20.4% for 2019 and 43% for 2020 over the past 60 days.
BeiGene’s loss per share estimates have been narrowed 2.2% for 2019 and 0.3% for 2020 over the past 60 days.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>